title: [The treatment of psoriasis: basic principles and new options].
abstract: Psoriasis is a frequent chronic disease with a typical cutaneous expression described as erythemato-squamous lesions, and sometimes, joint involvement. This disorder rarely causes death in patients, but often alters their quality of life. A better understanding of the pathophysiology of psoriasis has led to the development of new therapeutic options among which are treatments targeted on blocking T-cell activation. Thanks to these therapies we can offer the patients long lasting remission, albeit not a curative approach. The therapeutic approach towards psoriasis will be selected in a multidisciplinary spirit, and after considering the patient himself, his disease and his lifestyle.
authors.affiliation: Service de Dermatologie, C.H.U. Brugmann, Bruxelles.
authors.forename: P
authors.initials: P
authors.lastname: Vereecken
authors.forename: P
authors.initials: P
authors.lastname: Provost
authors.forename: F
authors.initials: F
authors.lastname: Willaert
authors.forename: M
authors.initials: M
authors.lastname: Heenen
authors.forename: J
authors.initials: J
authors.lastname: Bentin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000068800:Etanercept; D006073:Gout / Q000503:physiopathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000502:physiology; D011565:Psoriasis / Q000145:classification / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept